Cargando…
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 dia...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919219/ https://www.ncbi.nlm.nih.gov/pubmed/33371732 http://dx.doi.org/10.1177/1479164120971220 |
_version_ | 1783658092915851264 |
---|---|
author | Hiramatsu, Takeyuki Ito, Hiroki Okumura, Shota Asano, Yuko Iguchi, Daiki Furuta, Shinji |
author_facet | Hiramatsu, Takeyuki Ito, Hiroki Okumura, Shota Asano, Yuko Iguchi, Daiki Furuta, Shinji |
author_sort | Hiramatsu, Takeyuki |
collection | PubMed |
description | INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. MATERIALS AND METHODS: A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1): n = 72 or Group S (SGLT-2 inhibitor)—dapagliflozin (n = 52) or empagliflozin (n = 32). Renal function was assessed every 3 months for 36 months. Cardiovascular parameters were evaluated every 12 months for 36 months. RESULTS: Compared with baseline, HbA1c and systolic blood pressure significantly decreased in both groups (p < 0.05). The estimated glomerular filtration rate decreased, but without significance. Albuminuria decreased significantly in both groups and then subsequently increased after 30 months in Group S. Diastolic cardiac function, assessed by E/e′ or left atrial volume index, decreased only in Group G at 36 months. CONCLUSIONS: The GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months. |
format | Online Article Text |
id | pubmed-7919219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-79192192021-03-02 Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment Hiramatsu, Takeyuki Ito, Hiroki Okumura, Shota Asano, Yuko Iguchi, Daiki Furuta, Shinji Diab Vasc Dis Res Original Article INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. MATERIALS AND METHODS: A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1): n = 72 or Group S (SGLT-2 inhibitor)—dapagliflozin (n = 52) or empagliflozin (n = 32). Renal function was assessed every 3 months for 36 months. Cardiovascular parameters were evaluated every 12 months for 36 months. RESULTS: Compared with baseline, HbA1c and systolic blood pressure significantly decreased in both groups (p < 0.05). The estimated glomerular filtration rate decreased, but without significance. Albuminuria decreased significantly in both groups and then subsequently increased after 30 months in Group S. Diastolic cardiac function, assessed by E/e′ or left atrial volume index, decreased only in Group G at 36 months. CONCLUSIONS: The GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months. SAGE Publications 2020-12-29 /pmc/articles/PMC7919219/ /pubmed/33371732 http://dx.doi.org/10.1177/1479164120971220 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Hiramatsu, Takeyuki Ito, Hiroki Okumura, Shota Asano, Yuko Iguchi, Daiki Furuta, Shinji Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment |
title | Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment |
title_full | Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment |
title_fullStr | Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment |
title_full_unstemmed | Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment |
title_short | Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment |
title_sort | impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919219/ https://www.ncbi.nlm.nih.gov/pubmed/33371732 http://dx.doi.org/10.1177/1479164120971220 |
work_keys_str_mv | AT hiramatsutakeyuki impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment AT itohiroki impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment AT okumurashota impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment AT asanoyuko impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment AT iguchidaiki impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment AT furutashinji impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment |